Transform Pharmaceuticals

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website

Synta Pharmaceuticals Corp., based in Lexington, MA, specializes in developing pharmaceutical products aimed at treating cancer and inflammatory diseases. With a robust portfolio boasting over 700 issued or pending patents, the company stands out for its innovative approach to drug development. Founded in 1992 by Dr. Lan Bo Chen, Synta Pharmaceuticals has established itself as a leader in the pharmaceutical industry, dedicated to advancing treatments for challenging medical conditions through cutting-edge research and development. Generated from their available business information

Kiniksa Pharmaceuticals is a biopharmaceutical company dedicated to addressing critical therapeutic needs for patients suffering from debilitating diseases. With a focus on immunemodulating assets, Kiniksa approaches its mission with a sense of urgency, understanding that every moment counts in the pursuit of better health outcomes. Headquartered in Lexington, Massachusetts, Kiniksa operates internationally with locations in the United Kingdom and Switzerland. The company emphasizes patient advocacy and strives to make every second matter in the development of innovative treatments for conditions such as recurrent pericarditis. Generated from the website